{
    "clinical_study": {
        "@rank": "87332", 
        "arm_group": {
            "arm_group_label": "PF-03084014 plus docetaxel", 
            "arm_group_type": "Experimental", 
            "description": "PF 03084014 will be administered orally, continuously, twice daily at doses from  80 to 150 mg  in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m^2"
        }, 
        "brief_summary": {
            "textblock": "This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel\n      combination in patients with advanced breast cancer. Preliminary information about the\n      efficacy of the combination will also be collected."
        }, 
        "brief_title": "A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of breast cancer with evidence of a) metastatic or b) locally\n             recurrent/advanced disease.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with a gamma secretase inhibitors or other Notch signaling\n             inhibitors."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876251", 
            "org_study_id": "A8641016"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-03084014 plus docetaxel", 
                "description": "Tablet, 10 mg, twice a day", 
                "intervention_name": "PF-03084014", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-03084014 plus docetaxel", 
                "description": "Tablet, 50 mg, twice a day", 
                "intervention_name": "PF-03084014", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-03084014 plus docetaxel", 
                "description": "Tablet, 100 mg, twice a day", 
                "intervention_name": "PF-03084014", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-03084014 plus docetaxel", 
                "description": "Solution for IV infusion 75 mg/m^2, every 3 weeks", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }, 
            {
                "arm_group_label": "PF-03084014 plus docetaxel", 
                "description": "Solution for IV infusion 100 mg/m^2, every 3 weeks", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Breast cancer metastatic", 
            "docetaxel", 
            "PF-03084014"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8641016&StudyName=A%20Study%20Evaluating%20The%20PF-03084014%20In%20Combination%20With%20Docetaxel%20In%20Patients%20With%20Advanced%20Breast%20Cancer"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27514"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599-7600"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20141"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Italy"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1B Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "First cycle dose limiting toxicity", 
                "measure": "Number of participants with Dose-limiting toxicities (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "description": "The period from study entry until disease progression, death or date of last contact.", 
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876251"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "QTc duration", 
                "measure": "QTc Interval", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Change in gene expression levels", 
                "measure": "Changes in gene expression levels (PD biomarkers)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Change in analyte expression", 
                "measure": "Changes in analyte levels from baseline to post-treatment (PD biomarkers)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Percentage of Participants With Objective Response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Duration of Response (DR)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}